The biotechnology sector is undergoing significant transformation, marked by substantial technological advancements and major economic challenges. The integration of artificial intelligence (AI) into research and development (R&D) processes has become a critical strategic lever to overcome the obstacles posed by the "patent cliff," which threatens to reduce industry revenues by $400 billion. Recent innovations, such as the AI-generated synthetic DNA in Belgium and the development of hierarchical AI systems for bacterial analysis in Italy, illustrate the transformative potential of these technologies.